EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Cascade genetic testing for hereditary cancer syndromes: a review of barriers and breakthroughs

Rachel Levine, Ryan M Kahn, Luiza Perez, Jesse Brewer, Samantha Ratner, Xuan Li, Effi Yeoshoua, Melissa K Frey

Familial Cancer · 2024-06 · 23 (2) · 111-120

DOI: 10.1007/s10689-024-00373-4 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Familial Cancer, online erschienen am 26.03.2024. Verfasst von Rachel Levine und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, HCA Florida Brandon, Brandon, FL, USA. rachel.levine@hcahealthcare.com. Hauptthemen laut MEDLINE: Genetic Testing, Neoplastic Syndromes, Hereditary, Genetic Predisposition to Disease. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 110 Literaturangaben. Gefördert von: American Association of Obstetricians and Gynecologists Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Germline genetic sequencing is now at the forefront of cancer treatment and preventative medicine. Cascade genetic testing, or the testing of at-risk relatives, is extremely promising as it offers genetic testing and potentially life-saving risk-reduction strategies to a population exponentially enriched for the risk of carrying a cancer-associated pathogenic variant. However, many relatives do not complete cascade testing due to barriers that span individual, relationship, healthcare community, and societal/policy domains. We have reviewed the published research on cascade testing. Our aim is to evaluate barriers to cascade genetic testing for hereditary cancer syndromes and explore strategies to mitigate these barriers, with the goal of promoting increased uptake of cascade genetic testing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TestingNeoplastic Syndromes, HereditaryGenetic Predisposition to DiseaseHumansGerm-Line MutationGenetic Counseling

Stichwörter der Autor:innen

Cascade genetic testingHereditary cancer syndromesPredictive testing

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, HCA Florida Brandon, Brandon, FL, USA. rachel.levine@hcahealthcare.com.
  • Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Division of Gynecologic Oncology, Weill Cornell Medicine, New York, NY, USA.
  • Genetics and Personalized Cancer Prevention Program, Weill Cornell Medicine, New York, NY, USA.

Förderung

  • American Association of Obstetricians and Gynecologists Foundation

Zitieren

APA

Levine, R., Kahn, R. M., Perez, L., Brewer, J., Ratner, S., Li, X., Yeoshoua, E., & Frey, M. K. (2024). Cascade genetic testing for hereditary cancer syndromes: a review of barriers and breakthroughs. Familial Cancer, 23(2), 111-120. https://doi.org/10.1007/s10689-024-00373-4

Vancouver

Levine R, Kahn RM, Perez L, Brewer J, Ratner S, Li X, et al. Cascade genetic testing for hereditary cancer syndromes: a review of barriers and breakthroughs. Familial Cancer. 2024;23(2):111-120. doi:10.1007/s10689-024-00373-4

BibTeX
@article{Levine2024,
  author = {Levine, Rachel and Kahn, Ryan M and Perez, Luiza and Brewer, Jesse and Ratner, Samantha and Li, Xuan and Yeoshoua, Effi and Frey, Melissa K},
  title = {Cascade genetic testing for hereditary cancer syndromes: a review of barriers and breakthroughs},
  journal = {Familial Cancer},
  year = {2024},
  volume = {23},
  number = {2},
  pages = {111--120},
  doi = {10.1007/s10689-024-00373-4}
}
Kostenlos starten →